CPI 444

Drug Profile

CPI 444

Alternative Names: Adenosine A2A Receptor Antagonist - Corvus; CPI444; Immune checkpoint inhibitor A; V 81444

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer Corvus Pharmaceuticals; Genentech; Vernalis
  • Class Antineoplastics; Antiparkinsonians; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Cancer
  • No development reported Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 17 Nov 2017 Roche plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia, South Korea, France, Spain, United Kingdom and USA in December 2017 (NCT03337698)
  • 14 Nov 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia (PO) (NCT03337698)
  • 11 Nov 2017 Updated efficacy, adverse events and biomarker analysis data from a phase I/Ib trial in Solid tumours released by Corvus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top